Midterm 2 Flashcards
(54 cards)
diuretics
– nursing non-pharmacological therapy and care
renal diet
- ↓ protein (urea), K, phosphorus, and Mg diet
- Na+ restriction
- fluid restriction
- stop nephrotoxic meds
diuretics
– therapeutic actions and pathophysiology
loop
- blocks absorption of Na, K, Cl
- ↑diuresis
- ↓ edema, HTN, HF
thiazide
- blocks Na; ↓H2O
- ↓ edema, HTN
potassium-sparing
- promote retention of K
- aldosterone antagonists
diuretics
– nursing role in pharmacological management
tx primary cause of the problem
- w/ CV drugs
diuretics
- assess kidney function
- ↑urinary output
edema, dehydration
diuretics
– renal failure
- nephrotoxic medications to be stopped
> NSAIDS, ACE inhibitors - average dose = fatal
diuretics
- furosemide
loop
mech of action:
- prevents reabsorption of Na & Cl
therapeutic effects:
- acute edema
- HTN, HF
adverse effects:
- electrolyte imbalance
- orthostatic hypotension
- syncope from hypovolemia
diuretics
– spironolactone
K sparring
mech of action:
- inhibits action of aldosterone
- Na, Cl, H2O excretion are ↑, K retained
therapeutic effect:
- mild HTN
adverse effects:
- hyperkalemia
- muscle weakness, paralysis
- paresthesia
- tachycardia
- headache, dizziness, N
- gynecomastia
diuretics
– mannitol
osmotic
mech of action:
- ↑the [of filtrates] in the kidneys and ↓the reabsorption of H2O and Na
therapeutic effects:
- draws out fluid from EVS into blood vessels
- ↓intra cranial pressure
adverse effects:
- overdose = shift of fluid to the vascular compartment > HF or pulmonary edema
- electrolyte imbalance
- hypovolemia, dehydration, tachy
- fatigue, dizziness
- N/V
- convulsions
diuretics
– hydrochlorothiazide
thiazide
mech of action:
- acts on kidney tubules
- prevents reabsorption of Na
therapeutic effects:
- HTN
- fluid retention s/o to HF, liver disease, corticosteroid and estrogen therapy
adverse effects:
- electrolyte imbalance
- high blood glucose
- alcohol potentiated the effect
- dizziness
- weakness
diuretics
– nursing assessment, planning, and intervention
assessment:
- health hx
- baseline VS
- obtain blood and urine samples
planning:
- pt to exhibit normal fluid & electrolyte balance during therapy
- education regarding action, precautions, and adverse effects
- sx of hypokalemia, hyperkalemia, hypersensitivity
intervention:
- electrolyte levels
- VS > BP
- changes in LOC
- I&O
- K intake, K levels
coagulation
– primary mech. by which coagulation-modifying drugs act
anticoagulant
- inhibition of specific clotting factors
anticoagulant/antiplatelet
- inhibition of platelet action
thrombolytic
- dissolving the clot
antifibrinolytic
- inhibition of the destruction of fibrin
coagulation
– explain therapeutic action of each class of drug used in relation to the pathophysiology of coagulation (thromboembolic) disorders
anticoagulant
- prevention of clot formation
anticoagulant/antiplatelet
- prevention of clot formation
thrombolytic
- removal of existing clot
antifibrinolytic
- promotion of clot formation
coagulation
– INR, aPPT
INR:
an pts whose blood clots normally and who is not on anticoagulation should have an INR of approx. 1.
- The higher your INR is, the longer it takes your blood to clot
- INR target range for someone on warfarin is somewhere between 2.0 and 4.0.
aPPT:
- activated partial thromboplastin time
- also measures the speed of clotting but differs from the PT test in that it aims to establish how blood clots within a blood vessel
- heparin
coagulation
– nursing role in pharmacotherapy
- health hx
- baseline VS, HR + BP and clotting times
- adverse effects
- bleeding
– coagulation
Heparin
mech of action:
- activates antithrombin II which inhibits thrombin
- prevents clot formation
- antidote = protamine sulfate
therapeutic effects:
- after MI, after DVT
- prophylaxis
adverse effects:
- bleeding
- osteoporosis
- HIT
coagulation
– Warfarin
mech of action:
- inhibits/blocks 2 enzymes that use vit K to produce clotting factors
therapeutic effects:
- DVT, pulmonary embolism
- prevention of CVA/MI
adverse effects:
- micro embolism > purple toe syndrome
- osteoporosis
- abnormal bleeding
drug-food
- avoid green foods which are high in vit K
coagulation
– apixaban
mech of action:
- direct Xa inhibitor
therapeutic effects:
- slow/decrese the risk for strokes
adverse effects:
- severe bleeding
- no antidote
coagulation
– clopidogrel
mech of action:
- blocks ADP receptor on platelets inhibiting platelet activation and aggregation, thereby extending clotting times
therapeutic effects:
- reduce risk of CVA/MI
- reducing thrombolytic events post CVA/MI
- prevent DVT
- unstable angina/coronary stents
adverse effects:
- headache/dizziness
- diarrhea
- upper resp tract infections
- rash, pruritis
coagulation
– alteplase
mech of action:
- converts plasminogen to plasmin which breaks down fibrin in clot
- ↓circulating fibrinogen and plasminogen
therapeutic effects:
- the only clot buster
- thrombotic CVA
- off label use > restore IV catheter patency
adverse effects:
- angioedema
- intercranial bleeding
coagulation
– ticagrelor
mech of action:
- ADP receptor antagonists
therapeutic effects:
- antiplatelet drug
- MI, stroke
- prophylaxis
adverse effects:
- hypersensitivity reactions
- bleeding
- dyspnea
coagulation
– aminocaproic acid
mech of action:
- inactivates plasminogen precursor for plasmin that digests the fibrin clot
therapeutic effects:
- antifibrinolytic
- acute hemorrhages
adverse effects:
- usually mild
- thrombophlebitis (IV)
- muscle weakness and wasting
- thrombotic event
coagulation
– ADPIE
assessment:
- health hx
-
planning
coagulation
– LMWH
- fewer adverse effects than heparin
- not IV
- decreased risk for thrombocytopenia
ex: enoxaparin, daltaparin
immune system
– immunostimulants vs immunosupressants
immunostimulants:
- ↑ the ability of the immune system to fight infection/disease
- pts w/ cancer, vaccines
immunosuppressants:
- diminish the ability of the immune system to fight infection & disease
- transplant pts to prevent organ rejection
- lupus, RA
immune system
– nursing considerations in the implementation of immunosuppressant therapy
toxic to bone marrow
- WBC, RBC, platelets
> anemia, leukopenia, thrombocytopenia
risk for infection
assess:
- metastatic cancer, active infections, liver/kidney disease, pregnancy